2301-PUB: Efficacy of HbA1c Changes, Weight Changes, and Blood Pressure Changes in GLP-1RA Daily Treatment or GLP-1RA Weekly Treatment in Type 2 Diabetes.

Aims: To evaluate the efficacy of GLP-1 receptor agonist daily treatment or GLP-1 receptor weekly treatment in type 2 diabetes. Methods: A systematic search of MEDLINE, Embase and Cochrane Central Register of Controlled Trials was made from the beginning date to December 2018. Results: A total of 111 studies were included in the meta-analysis. Compared with placebo, treatment with GLP-1RA daily led to significant decrease in HbA1c from baseline (WMD, -0.78%, P<0.01), significant decrease in weight (WMD, -0.97kg, P<0.01), significant decrease in SBP (WMD, -2.41mmHg, P<0.01). Compared with placebo, treatment with GLP-1RA weekly resulted in significant decrease in HbA1c from baseline (WMD, -1.00%, P<0.01), significant decrease in weight (WMD, -1.33kg, P<0.01), significant decrease in SBP (WMD, -1.41mmHg, P<0.01) (Table 1). Conclusion: Compared with placebo, in type 2 diabetes patients, treatment with GLP-1 receptor agonist daily and weekly, both resulted in significant decrease in HbA1c, weight and SBP from baseline. Disclosure: X. Cai: None. W. Yang: None. S. Zhang: None. L. Ji: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck KGaA, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk A/S, Roche Pharma, Sanofi, Takeda Pharmaceutical Company Limited. Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Roche Pharma, Sanofi. [ABSTRACT FROM AUTHOR]